Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Forterra lifts profit forecasts after housing recovery boosts H1 sales

(Sharecast News) - Forterra's share price jumped 11% on Tuesday after the building materials group raised full-year targets on the back of a strong first-half performance, with sales surging by a fifth. Chief executive Neil Ash hailed a "strong uplift in results" over the six months to 30 June, as improved demand from the volume housebuilding sector offset subdued activity in the repair, maintenance and improvement sectors, with UK brick industry despatches well ahead of last year.

"Looking beyond the current financial year, the Board remains confident that its recent investments in new production capacity leave the Group well placed to benefit from the continuing recovery of our key markets," Ash said.

With demand for Forterra's products said to be both ahead of the previous year and its previous expectations, second-half adjusted EBITDA is now expected to be modestly ahead of the first half.

The new outlook implies a full-year adjusted EBITDA figure of c.£60-61m, according to broker Peel Hunt, which it said was "5-7% ahead of our current forecast and c.3% ahead of consensus".

"This is expected to translate to adjusted PBT being significantly ahead of previous expectations due to broadly fixed depreciation and amortisation and reducing finance expense," the company said, though did not disclose any specific guidance.

The company, which specialises in products like clay bricks, concrete blocks and precast concrete flooring, said revenues jumped by 20.4% year-on-year to £195.1m in the first half, helped by strong volume growth and a modest increase in sales prices.

Adjusted EBITDA rose 23% to £29.9m, helped by a 30-basis point improvement in the adjusted EBITDA margin to 15.3%.

Meanwhile, operating cash flow surged 125.6% to £30m, leading to a bigger reduction in debt thant predicted, with net debt before leases falling to £69.4m from £84.9m at the end of 2024.

The stock was up 11% at 204p by 1244 BST, hitting its highest levels since March 2023.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.